The shareholders, members of the Interfaith Center on Corporate Responsibility, have been trying to get the healthcare juggernaut to share more information about its controversial business practices for more than a year.
Faith-based investor coalition sues UnitedHealth to force disclosure of M&A impacts Read More »
This year’s catalysts in the space include a near-term FDA decision on Eli Lilly’s oral challenger to the new Wegovy pill. Looking further ahead, Novo Nordisk is expecting more clinical data for next-gen weight loss asset CagriSema, which recently lost a head-to-head battle with Lilly’s Zepbound.
Despite Novo’s Robust Oral Wegovy Launch, Access Remains a Challenge for Obesity Drugs Read More »
Looking for a biopharma job in New York? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.
La biopsia líquida ha dejado de ser una promesa lejana. Hoy se abre paso en hospitales, centros de investigación y laboratorios clínicos como una herramienta de gran valor para detectar señales tempranas de cáncer a partir de una muestra de sangre. La idea es simpl …
Avances en biopsia líquida: La detección precoz del cáncer en los laboratorios actuales Read More »
Merck’s acquisition of Terns Pharmaceuticals follows other big-ticket purchases, including of Verona Pharma and Cidara Therapeutics, as the pharma prepares for the impending expiry of its blockbuster’s patents.
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms Read More »
While RA Capital Management has yet to commit to a merger plan, it noted that its new blank-check company, Research Alliance III, could target companies abroad, including those from China.
RA Capital Looks to China for Next Startup To Put on SPAC Track to Nasdaq Read More »
Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval for Xpovio in myelofibrosis, according to Jefferies analysts.
Karyopharm Slides as Mixed Myelofibrosis Results Cloud Regulatory Road Read More »
Un estudio reciente revela que, en contra de lo que se ha venido creyendo, esos pájaros carroñeros no siguen sistemáticamente a los lobos y a otros depredadores cuando buscan sitios con restos de cadáveres de presas cazadas por estos, pero que, pese a ello, consiguen lleg …
Los inesperados conocimientos que los cuervos tienen sobre los lobos Read More »
El aburrimiento tiene mala reputación, pero la neurociencia lleva años revisando ese juicio. Lo que culturalmente tratamos como un estado pasivo y poco deseable resulta ser, desde el punto de vista cognitivo, una señal activa del sistema nervioso. El cerebro no se aburre por fal …
La ciencia detrás del aburrimiento y las nuevas formas de entretenimiento interactivo Read More »
Gilead continues its dealmaking spree in the sizzling hot space of I&I as Johnson & Johnson, along with partner Protagonist, notched an FDA approval for a new psoriasis drug. Plus, Aurinia Pharmaceuticals gets a new C-suite, FDA releases draft guidance on non-animal models and the CDC’s vaccine advisory committee is not being disbanded after all.
Gilead’s Ouro Buy, J&J/Protagonist’s Approval, Aurinia’s Revamp, ACIP Confusion, More Read More »
